The results from the Cevira Phase 2b study were presented by one of the main study investigators, Dr Philipp Soergel from University of Hannover. The study included 262 patients with cervical intraepithelial neoplasia caused by oncogenic HPV infections. The clinical benefit of Cevira in patients diagnosed with high-risk disease defined as CIN2, was the main focus of Dr Soergel’s presentation.
The presentation concluded that Cevira demonstrates a clinical important benefit in this population applying two key clinical outcome metrics, histological regression and absence of oncogenic HPV infection. These results support previous analyses, showing the robustness of the Cevira response data in patients with cervical high-risk disease